A Picture is Worth a Thousand Words
This article was originally published in RPM Report
Executive Summary
One FDA advisory committee urges a sponsor to get graphic in its REMS for a weight loss drug. Another committee rejects an expanded label after FDA shows a picture of the risk in its presentation.
You may also be interested in...
Setting the Stage: Qnexa and the Power of REMS
Vivus’ second trip to an advisory panel was a much happier one, with the company’s weight loss therapy garnering an overwhelming “yes” vote on approvability. The key change? A Risk Evaluation & Mitigation Strategy that will be precedent setting if approved—and that demonstrates the power of REMS even if FDA moves in a different direction with this application.
Amgen Needs To Show Xgeva Does More Than Delay Bone Metastases, ODAC Says
Measurement of a downstream endpoint, such as delay in skeletal-related events, could have been better than radiographic scans to assess efficacy of denosumab in delaying bone metastases in high-risk castration-resistant prostate cancer patients, several ODAC members contend.
Rx List Price Inflation Penalty Endorsed By US HHS Secretary
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: